Online inquiry

IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ8496MR)

This product GTTS-WQ8496MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ITGAL gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001114380.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3683
UniProt ID P20701
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ8496MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12433MR IVTScrip™ mRNA-Anti-IFNG, NI-0501(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NI-0501
GTTS-WQ11481MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ3049MR IVTScrip™ mRNA-Anti-PTK7, Anti-PTK7 ADC(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Anti-PTK7 ADC
GTTS-WQ11129MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MDX-1103
GTTS-WQ4862MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ3268MR IVTScrip™ mRNA-Anti-TNF, ART621(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ART621
GTTS-WQ7163MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ8420MR IVTScrip™ mRNA-Anti-HSP90, HSP90mab(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HSP90mab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW